Arcagy/ Gineco Group
Clinical trials sponsored by Arcagy/ Gineco Group, explained in plain language.
-
When to operate? ovarian cancer trial tests best time for surgery after chemo
Disease control CompletedThis trial studied 211 women with advanced ovarian cancer who were not candidates for upfront surgery. Researchers compared having surgery after 3 rounds of chemotherapy versus after 6 rounds. The goal was to see which timing leads to longer disease-free survival. All patients re…
Phase: NA • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Immunotherapy combo shows promise in ovarian cancer trial
Disease control CompletedThis study tested two immunotherapy drugs, durvalumab and tremelimumab, given with chemotherapy before and after surgery for advanced ovarian cancer. The goal was to see if this combination is safe and feasible. About 69 women with stage IIIC to IV ovarian cancer took part. The r…
Phase: PHASE1, PHASE2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Immunotherapy combo shows promise in Hard-to-Treat ovarian cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before surgery helps women with advanced ovarian cancer. About 91 participants received either chemo alone or chemo plus pembrolizumab. The goal was to see if the combination…
Phase: PHASE2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
Ovarian cancer genetics under the microscope: no treatment, just knowledge
Knowledge-focused CompletedThis study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how genetic changes in their tumors relate to how the disease progresses. Researchers collected tumor samples and medical data to find links between DNA abnormalities and outcomes …
Sponsor: ARCAGY/ GINECO GROUP • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:10 UTC